1. SafetyInformation such as the type; frequency and severity of adverse events that occurred from the time of the first inoculation of the investigational drug to 8 weeks after the first inoculation will be collected to evaluate the safety.2. ImmunogenicityRate of change from baseline in SARS-CoV-2 spike (S) glycoprotein-specific antibody titers 2 weeks after the first inoculation of the investigational drug (immediately before the second inoculation); 4 weeks; 6 weeks; and 8 weeks Analyze and assess immunogenicity.

1. SafetyInformation such as the type; frequency and severity of adverse events that occurred from the time of the first inoculation of the investigational drug to 8 weeks after the first inoculation will be collected to evaluate the safety.2. ImmunogenicityRate of change from baseline in SARS-CoV-2 spike (S) glycoprotein-specific antibody titers 2 weeks after the first inoculation of the investigational drug (immediately before the second inoculation); 4 weeks; 6 weeks; and 8 weeks Analyze and assess immunogenicity.